{"id":278962,"date":"2025-10-05T07:00:14","date_gmt":"2025-10-05T07:00:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/278962\/"},"modified":"2025-10-05T07:00:14","modified_gmt":"2025-10-05T07:00:14","slug":"tempus-ai-inc-tem-secures-fda-clearance-for-xr-ivd-device-to-enhance-drug-discovery","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/278962\/","title":{"rendered":"Tempus AI, Inc. (TEM) Secures FDA Clearance for xR IVD Device to Enhance Drug Discovery"},"content":{"rendered":"\n

Tempus AI, Inc. (NASDAQ:TEM<\/strong><\/a>) is one of the best Nancy Pelosi stocks to buy right now<\/strong><\/a>. On September 22, the company received 510(K) clearance from the US Food and Drug Administration. The clearance covers the RNA-based Tempus xR IVD device, being offered as a life sciences tool for enhancing drug development programs.<\/p>\n

\"Tempus Tempus AI, Inc. (TEM) Secures FDA Clearance for xR IVD Device to Enhance Drug Discovery <\/p>\n

Copyright: dolgachov \/ 123RF Stock Photo<\/a><\/p>\n

With the clearance, the company\u2019s partners can leverage the RNA essay to identify which patients are likely to respond to specific therapies and design more efficient clinical trials. As more therapies tied to RNA biomarkers enter the market, they should become preferred treatment options for people with cancer.<\/p>\n

The FDA authorization confirms Tempus Edge as a one-stop shop for precision medicine solutions. That\u2019s because xR IVD is one of the solutions applied to advanced oncology therapeutic research and development.<\/p>\n

\n

\u201cWe have long known that RNA sequencing offers additional insights beyond DNA alone, but only now are we beginning to unlock its full value in supporting therapeutic development. This FDA clearance further demonstrates the promise of RNA sequencing and opens up new opportunities for us with our biopharma customers,\u201d said Kate Sasser, PhD, Chief Scientific Officer at Tempus.<\/p>\n<\/blockquote>\n

Tempus AI, Inc. (NASDAQ:TEM) boasts an extensive library of clinical and molecular data to power precision medicine, enabling physicians to make more informed treatment decisions and accelerate the discovery of new drugs. It provides clinicians with tools to analyze patient data and supports researchers in identifying new drug targets and conducting clinical trials.<\/p>\n

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/b><\/a>.<\/p>\n

READ NEXT: <\/b>12 Cheap AI Stocks to Buy Right Now<\/strong><\/a> and <\/b>10 Best Performing ASX Stocks in 2025<\/strong><\/a>.<\/p>\n

Disclosure: None. This article is originally published at\u00a0Insider Monkey<\/b><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Tempus AI, Inc. (NASDAQ:TEM) is one of the best Nancy Pelosi stocks to buy right now. On September…\n","protected":false},"author":3,"featured_media":278963,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[691,44423,738,59971,82260,158,144209,144208,67,132,68],"class_list":{"0":"post-278962","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-artificial-intelligence","8":"tag-ai","9":"tag-ai-stock","10":"tag-artificial-intelligence","11":"tag-nancy-pelosi","12":"tag-rna-sequencing","13":"tag-technology","14":"tag-tem","15":"tag-tempus","16":"tag-united-states","17":"tag-unitedstates","18":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115320273171550435","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/278962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=278962"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/278962\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/278963"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=278962"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=278962"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=278962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}